This episode bridges the gap between clinical trial data and everyday practice, focusing on how pediatricians can systematically ensure no eligible infant falls through the cracks. This episode ...
Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report. A recent analysis of national ...
A look back at the FDA approvals, label expansions, and regulatory decisions in the pediatric health care space from April through June 2026. Spring gave way to summer, and along the way the FDA kept ...
New RSV shots and monoclonals cut infant hospitalizations up to 85%, with strong real‑world safety—learn what efficacy vs effectiveness really means. This episode provides a clear-eyed analysis of ...
A look back at the latest clinical trial updates for the pediatric population during June 2026. June brought a more concentrated set of clinical trial developments than earlier in the quarter, with ...
The July 1, 2026 decision makes exagamglogene autotemcel the first gene therapy approved for SCD in children younger than 12 years. The FDA has issued a supplemental approval for Casgevy ...
In this episode, Dr. Simões reviews the post-licensure landscape, highlighting data from real-world effectiveness studies now emerging from multiple countries. Initial real-world data for one ...
Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
Meta-analysis finds no causal association between antidepressant use in pregnancy and neurodevelopmental disorders ...
The PANDAS/PANS questionnaire is based on symptoms and comorbidities described in the literature and is a self-report completed by parents of children younger than 18. "Bottom line, previous surgery ...
Across all years in the report, the CDC rated each physical activity trend with a color of red, indicating that trends are going in the "wrong direction." The Youth Risk Behavior Survey (YRBS) Data ...
Thomas Crawford, MD, highlights improved motor function with apitegromab for spinal muscular atrophy
Thomas Crawford, MD, said SAPPHIRE trial data show apitegromab provides clinically meaningful strength gains for children with SMA by targeting muscle in addition to motor neurons. The study enrolled ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results